Delta sleep-inducing peptide, or DSIP, was studied in small human sleep experiments during the 1970s and 1980s. Results were mixed, the clinical literature is dated, and the reviewed record does not establish DSIP as a sleep treatment.
Research peptide
DSIP
Delta sleep-inducing peptide, or DSIP, was studied in small human sleep experiments during the 1970s and 1980s. Results were mixed, the clinical literature is dated, and the reviewed record does not establish DSIP as a sleep treatment.
Regulatory watch
Last reviewed Jul 12, 2026
Next review Jul 24, 2026
Evidence snapshot
Human evidence: small sleep studies from the 1970s and 1980s reported mixed and inconclusive findings.
Modern replication: no contemporary randomized clinical program was identified in the reviewed sources.
Regulatory status: DSIP is not FDA-approved and was scheduled for FDA advisory committee discussion in July 2026.
Research record
What the evidence record says
- Evidence grade
- Not Graded
- Regulatory status
- DSIP regulatory status has not been fully reviewed by Peptide Report editorial team. See company profiles and regulatory watch for current status.
Evidence records
Studies, registries, reviews, and regulatory records
Evidence review pending
- Detailed evidence review for DSIP is pending editorial assessment. Current summary reflects available public records.
Records: FDA compounding advisory committee July 2026: peptides, FDA BPC-157 compounding safety risk: immunogenicity, Effects of DSIP on sleep in humans: clinical sleep studies
Evidence timeline
What changed, and when
Peptide Report last reviewed DSIP on 2026-07-12.
Records: FDA compounding advisory committee July 2026: peptides
Direct answers
Frequently asked questions
What is DSIP?
DSIP is a research peptide tracked by Peptide Report. See the full profile for current editorial assessment.
Open research questions
What is still unknown
- What is the complete human evidence base for DSIP?
- What are the long-term safety considerations for DSIP?
Tracked claims
DSIP is listed for FDA advisory committee peptide discussion.
Evidence level: Primary regulatory
Sources: FDA compounding advisory committee July 2026: peptides
How to read this: Committee review is a regulatory proceeding, not evidence of approval or clinical benefit.
Early clinical studies reported that DSIP may influence sleep patterns, but results were mixed and inconclusive.
Evidence level: Peer reviewed
Sources: Effects of DSIP on sleep in humans: clinical sleep studies
How to read this: The DSIP clinical literature is dated to the 1970s-1980s and has not been advanced with modern randomized controlled trials. Treat sleep-promotion claims cautiously.
DSIP is discussed in online wellness communities as a sleep aid despite the lack of modern clinical evidence supporting its use.
Evidence level: Community discussion
Sources: Delta-sleep-inducing peptide: pharmacology and biological activity review, FDA BPC-157 compounding safety risk: immunogenicity
How to read this: Pharmacology reviews describe DSIP as a nonapeptide with reported sleep-modulating activity, but clinical significance remains unestablished. The FDA bulk risk list applies to compounded peptide products.
Linked public records
Regulatory actions involving DSIP
FDA advisory committee to review seven peptide-related bulk drug substances
Scheduled · Scheduled public meeting
FDA scheduled a two-day Pharmacy Compounding Advisory Committee meeting to discuss whether BPC-157, KPV, TB-500, MOTS-c, emideltide/DSIP, Semax, and Epitalon-related substances should be included on the 503A Bulks List. The committee provides advice; the meeting itself is not a final agency determination.
Compounds: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon
Free report
Get the source-quality checklist
Use the same checklist Peptide Report uses to separate DSIP claims, source records, supplier documentation, and media signals.
V1 collects email, role, and topic interest only. No medication, health-condition, dosing, or current-use data is collected in this form.
Formspree processes this submission for Peptide Report. Privacy notice.
Sources on this page
Each source record is linked to the claim or evidence note it supports.
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA Pharmacy Compounding Advisory Committee meeting notice for July 23 to 24, 2026, scheduling peptide bulk substances for discussion.
23 linked pagesOpen original ·
fda-pcac-july-2026Certain bulk drug substances for use in compounding may present significant safety risks
FDA risk page lists BPC-157: compounded BPC-157 may pose immunogenicity risk and peptide-related impurity concerns for certain routes of administration.
41 linked pagesOpen original ·
fda-bulk-risk-listEffects of DSIP on sleep in humans: clinical sleep studies
Clinical studies of delta sleep-inducing peptide (DSIP) in human sleep, dating to the 1970s-1980s, with mixed and inconclusive results. The DSIP clinical literature is old and has not been advanced with modern trials.
4 linked pagesOpen original ·
pubmed-dsip-clinical-sleep-1984Delta-sleep-inducing peptide: pharmacology and biological activity review
Reviews of DSIP pharmacology describe it as a nonapeptide isolated from rabbit brain extract with reported sleep-modulating activity, though clinical significance remains unestablished.
4 linked pagesOpen original ·
pubmed-dsip-pharmacology-reviewRelated compounds
BPC-157
BPC-157 is an experimental peptide with extensive animal research but very limited human evidence. A Phase 1 registry re...
Regulatory watchEpitalon
Epitalon is a synthetic tetrapeptide promoted for longevity and telomere-related effects. The reviewed evidence rests la...
Regulatory watchKPV
KPV is a three-amino-acid fragment derived from alpha-melanocyte-stimulating hormone. Anti-inflammatory findings come fr...
Regulatory watchSemax
Semax is a synthetic ACTH-derived peptide registered as a medicine in Russia. Cognitive and attention claims rely mainly...
Regulatory watchStay informed